Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer ; volume:6 ; number:1 ; day:15 ; month:9 ; year:2006 ; pages:1-8 ; date:12.2006
BMC cancer ; 6, Heft 1 (15.9.2006), 1-8, 12.2006
- Urheber
-
Orlando, Laura
- Beteiligte Personen und Organisationen
-
Cardillo, Anna
Ghisini, Raffaella
Rocca, Andrea
Balduzzi, Alessandra
Torrisi, Rosalba
Peruzzotti, Giulia
Goldhirsch, Aron
Pietri, Elisabetta
Colleoni, Marco
SpringerLink (Online service)
- DOI
-
10.1186/1471-2407-6-225
- URN
-
urn:nbn:de:1111-2016030339773
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:33 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Orlando, Laura
- Cardillo, Anna
- Ghisini, Raffaella
- Rocca, Andrea
- Balduzzi, Alessandra
- Torrisi, Rosalba
- Peruzzotti, Giulia
- Goldhirsch, Aron
- Pietri, Elisabetta
- Colleoni, Marco
- SpringerLink (Online service)
Ähnliche Objekte (12)
Survival in patients with non-metastatic breast cancer treated with adjuvant trastuzumab in clinical practice
Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer
Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population
Potential neurotoxicity associated with methotrexate
Systemic high-dose intravenous methotrexate in patients with central nervous system metastatic breast cancer
Effects of trastuzumab and trastuzumab emtansine on corrected QT interval and left ventricular ejection fraction in patients with metastatic (HER2+) breast cancer
Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2‑positive metastatic breast cancer
Successful Response to Cyclophosphamide, Vincristine, and Dacarbazine Chemotherapy in a Patient with Metastatic Carotid Body Paraganglioma
Phase II study of sequential S-1 and cyclophosphamide therapy in patients with metastatic breast cancer
Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china
Trastuzumab Administration in Patients with Metastatic Breast Cancer – Experience of a Large University Breast Center
Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial
Survival in patients with non-metastatic breast cancer treated with adjuvant trastuzumab in clinical practice
Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer
Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population
Potential neurotoxicity associated with methotrexate
Systemic high-dose intravenous methotrexate in patients with central nervous system metastatic breast cancer
Effects of trastuzumab and trastuzumab emtansine on corrected QT interval and left ventricular ejection fraction in patients with metastatic (HER2+) breast cancer
Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2‑positive metastatic breast cancer
Successful Response to Cyclophosphamide, Vincristine, and Dacarbazine Chemotherapy in a Patient with Metastatic Carotid Body Paraganglioma
Phase II study of sequential S-1 and cyclophosphamide therapy in patients with metastatic breast cancer
Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china
Trastuzumab Administration in Patients with Metastatic Breast Cancer – Experience of a Large University Breast Center
Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial
Survival in patients with non-metastatic breast cancer treated with adjuvant trastuzumab in clinical practice
Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer
Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population
Potential neurotoxicity associated with methotrexate
Systemic high-dose intravenous methotrexate in patients with central nervous system metastatic breast cancer
Effects of trastuzumab and trastuzumab emtansine on corrected QT interval and left ventricular ejection fraction in patients with metastatic (HER2+) breast cancer
Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2‑positive metastatic breast cancer
Successful Response to Cyclophosphamide, Vincristine, and Dacarbazine Chemotherapy in a Patient with Metastatic Carotid Body Paraganglioma
Phase II study of sequential S-1 and cyclophosphamide therapy in patients with metastatic breast cancer
Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china
Trastuzumab Administration in Patients with Metastatic Breast Cancer – Experience of a Large University Breast Center